Acrux

Advancing Women's Health Through Innovation

Acrux is an Australian specialty pharmaceutical company developing innovative transdermal medicines to address significant unmet medical needs.

Building on more than 25 years of pharmaceutical expertise, our lead development program is focused on advancing a novel, female-specific testosterone treatment for postmenopausal women.

Pioneering a New Approach to Women's Health

Acrux is advancing Female Testosterone MDTS, a novel transdermal spray being developed for postmenopausal women with hypoactive sexual desire disorder (HSDD).

With no FDA-approved testosterone treatment specifically for women in the United States, the program aims to address a significant unmet medical need.
Following recent regulatory engagement with the US FDA, Acrux is progressing towards Phase III clinical development.

Explore Female Testosterone MDTS

Over 25 Years of Pharmaceutical Innovation

Acrux has an established track record in developing and commercialising topical and transdermal medicines for international markets.

Our expertise spans proprietary drug delivery technologies, pharmaceutical development, regulatory pathways and global commercial partnerships.

The Acrux team in the laboratory

25+years of pharmaceutical expertise

1998Acrux established

2004listed on the ASX (ASX: ACR)

2007US FDA approval of our estradiol transdermal spray

Investor Centre

Investing in Pharmaceutical Innovation

Explore Acrux's investment proposition and stay informed about our progress through the latest ASX announcements, investor presentations, financial reports and shareholder information.

Latest News